Hi Eric,
There are a number of Cytoforum readers who regularly work with both CyTOF and RNAseq; hopefully some of them will chime in.
But, to get started, I think there are a couple points to make.
1. If I'm understanding you correctly, you're looking at the entire sample distribution (ie, all the junk gated out and you're looking at total LiveIntactSinglets or something similar). If so, then yes, the cells at very high expression relative to the rest of the population may indeed be biologically relevant (and correctly measured).
An example of this could be Plasmablasts, which are often considered to be CD27hi CD38hi relative to the rest of the CD3- CD19+ population. Add in the fact that Plasmablasts are often rare in a regular healthy donor PBMC sample, and they would be considered to be outliers by some definitions (especially if compared to the rest of the LiveIntactSinglets).
2. As you alluded to, Median vs Mean (vs Geometric Mean and others) have their assumptions about the shape of the data: unimodal vs bi/multimodal, symmetric vs asymmetric, presence or absence of long tails, etc.
Some of that is discussed in these links (to get you started):
https://voices.uchicago.edu/ucflow/2009 ... at-is-mfi/https://flowjo.typepad.com/the_daily_do ... n-mod.htmlhttps://www.cytometry.org/web/q_view.ph ... Techniques3. However, I don't know how useful these terms are at the level of a heterogeneous cell sample like total PBMC LiveIntactSinglets. In most cases in flow/mass cytometry, you're usually reporting Median or Mean once you have already gated down to some subset that's relatively heterogeneous in the marker you're interested in.
So, for instance, you might report MFI of pSTAT3 expression on total CD4+ after a stim in a Phospho experiment: a lot of phospho signals are pretty homogeneous at the level of a population like total CD4+.
However, reporting something like MFI of CD45RA expression on the same total CD4+ population wouldn't be very informative: Naive CD4+ have a very different CD45RA compared to Effector Memory CD4+.
4. I would also point out that in many (though not certainly all) cases, scRNAseq experiments are done on pre-sorted cells. So, before the scRNAseq even begins, you already have a relatively homogeneous population like total CD4+. Therefore, this may also be one of the differences that your eyes aren't quite trained to yet.
Mike